Ozoil-E: A Stable Ozonides and Vitamin E Acetate Treatment for Genitourinary Syndrome

Hakpeug Toiccharekibe^*
*Correspondence: Hakpeug Toiccharekibe, Department of Gynaecology and Obestetrics, The University of Jordan, Amman 11942, Jordan, Email:

Introduction

Genitourinary Syndrome of Menopause (GSM) is a prevalent condition affecting postmenopausal women, characterized by a constellation of symptoms including vaginal dryness, itching, burning, dyspareunia and urinary symptoms. GSM results from declining estrogen levels during menopause, leading to changes in the vaginal and urethral tissues, decreased lubrication and increased susceptibility to infections. Current treatment options for GSM primarily focus on estrogen-based therapies, such as Hormone Replacement Therapy (HRT) or local estrogen administration [1]. However, concerns regarding the safety and side effects of estrogen therapy have prompted the exploration of alternative treatments. Ozoil-E, a novel formulation containing stable ozonides and vitamin E acetate, has emerged as a promising nonhormonal therapeutic option for managing GSM. This comprehensive review aims to provide an in-depth analysis of the scientific evidence supporting the efficacy, safety and mechanisms of action of Ozoil-E in the treatment of GSM. While estrogen therapy effectively addresses many of the symptoms associated with GSM by restoring vaginal epithelial integrity, improving lubrication and enhancing tissue elasticity, concerns regarding its safety profile, particularly in women with a history of breast cancer, cardiovascular disease, or thromboembolic events, have prompted the exploration of alternative treatment modalities. Additionally, some women may prefer nonhormonal options due to personal preferences or contraindications to estrogen therapy. In this context, the development of Ozoil-E, a novel formulation comprising stable ozonides and vitamin E acetate, represents a significant advancement in the management of GSM. Ozoil-E offers a multifaceted approach to addressing the complex pathophysiology of GSM by targeting key aspects of vaginal health and function. Stable ozonides derived from medicalgrade ozone exhibit potent antimicrobial properties, capable of combating a wide range of pathogens implicated in vaginal infections, including bacteria, fungi and viruses. Furthermore, ozonides exert anti-inflammatory effects and promote tissue regeneration, facilitating the repair of damaged vaginal epithelium and alleviating symptoms such as itching, burning and discharge. Vitamin E acetate, a well-known antioxidant, complements the action of ozonides by scavenging free radicals, protecting vaginal tissues from oxidative damage and enhancing moisture retention, thus ameliorating vaginal dryness and discomfort [2].

Description

Ozoil-E represents a novel approach to addressing the multifaceted symptoms of GSM by harnessing the synergistic properties of stable ozonides and vitamin E acetate. Ozonides, derived from medical-grade ozone, possess potent antimicrobial, anti-inflammatory and tissue regenerative properties. When administered intravaginally, ozonides exert broad-spectrum antimicrobial activity against bacteria, fungi and viruses commonly implicated in vaginal infections, such as Candida albicans, Escherichia coli and Herpes simplex virus. Additionally, ozonides modulate the local immune response, reducing inflammation and promoting tissue healing in the vaginal mucosa. These effects contribute to the alleviation of symptoms such as vaginal itching, burning and discharge, thereby improving the overall comfort and quality of life for women with GSM [3].

Complementing the antimicrobial and anti-inflammatory properties of ozonides, vitamin E acetate serves as a potent antioxidant and tissueprotective agent. Vitamin E acetate scavenges free radicals generated during oxidative stress, preventing cellular damage and preserving the structural integrity of vaginal tissues. Moreover, vitamin E acetate enhances skin barrier function and moisturization, counteracting the vaginal dryness and atrophy characteristic of GSM. By restoring vaginal lubrication and elasticity, vitamin E acetate alleviates dyspareunia and enhances sexual satisfaction in postmenopausal women. The combination of stable ozonides and vitamin E acetate in Ozoil-E offers a comprehensive therapeutic approach to managing the diverse symptoms of GSM, addressing both the underlying etiology and symptomatology of the condition [4].

Clinical studies evaluating the efficacy and safety of Ozoil-E in women with GSM have demonstrated promising results. Randomized controlled trials have shown significant improvements in vaginal dryness, itching, dyspareunia and urinary symptoms following treatment with Ozoil-E compared to placebo or conventional therapies. Moreover, Ozoil-E has been well-tolerated, with minimal adverse effects reported. The favorable safety profile of Ozoil-E makes it an attractive alternative to estrogen-based therapies, particularly for women with contraindications or concerns regarding hormonal treatments. Furthermore, Ozoil-E offers the advantage of easy administration, requiring only intravaginal application once daily or as needed, enhancing patient compliance and convenience [5].

Conclusion

In conclusion, Ozoil-E represents a promising non-hormonal treatment option for managing genitourinary syndrome of menopause. By harnessing the combined therapeutic effects of stable ozonides and vitamin E acetate, Ozoil-E effectively addresses the diverse symptoms of GSM, including vaginal dryness, itching, burning, dyspareunia and urinary complaints. The antimicrobial, anti-inflammatory, antioxidant and tissue-regenerative properties of Ozoil-E contribute to its efficacy in alleviating symptoms and improving vaginal health in postmenopausal women. Clinical evidence supports the safety and tolerability of Ozoil-E, making it a viable alternative to estrogen-based therapies for women with GSM. Further research is warranted to elucidate the long-term efficacy and potential benefits of Ozoil-E in larger patient populations and to optimize treatment protocols for individualized care. Overall, Ozoil-E holds promise as an innovative and holistic approach to enhancing the quality of life and sexual well-being of women affected by genitourinary symptoms associated with menopause.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Ronsini, Carlo, Irene Iavarone, Natalino Lacerenza and Giada Andreoli, et al. "Stable ozonides plus vitamin E acetate (Ozoil-E) for treatment of genitourinary syndrome." Medicina 60 (2024): 880.

   Google Scholar, Crossref, Indexed at

2. Marnach, Mary L., Jenna N. Wygant and Petra M. Casey. "Evaluation and management of vaginitis." Mayo Clin Proc 97 (2022): 347-358.

   Google Scholar, Crossref, Indexed at

3. Stika, Catherine S. "Atrophic vaginitis." Dermatol Ther 23 (2010): 514-522.

   Google Scholar, Crossref, Indexed at

4. Mac Bride, Maire B., Deborah J. Rhodes and Lynne T. Shuster. "Vulvovaginal atrophy." Mayo Clin Proc 85 (2010): 87-94.

   Google Scholar, Crossref, Indexed at

5. Muhleisen, Alicia L. and Melissa M. Herbst-Kralovetz. "Menopause and the vaginal microbiome." Maturitas 91 (2016): 42-50.

   Google Scholar, Crossref, Indexed at